Evaluation of bleeding in patients receiving direct oral anticoagulants

References

• KearonCAklEAOrnelasJAntithrombotic therapy for VTE disease: CHEST guideline and expert panel reportChest2016149231535226867832
   PubMed Web of Science ®Google Scholar
• KirchhofPBenussiSKotechaD2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTSEur Heart J201637382893296227567408
   PubMed Web of Science ®Google Scholar
• JanuaryCTWannLSAlpertJS2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm SocietyCirculation201413023e199e26724682347
   PubMed Web of Science ®Google Scholar
• ConnollySJEzekowitzMDYusufSDabigatran versus warfarin in patients with atrial fibrillationN Engl J Med2009361121139115119717844
   PubMed Web of Science ®Google Scholar
• PatelMRMahaffeyKWGargJRivaroxaban versus warfarin in nonvalvular atrial fibrillationN Engl J Med20113651088389121830957
   PubMed Web of Science ®Google Scholar
• GrangerCBAlexanderJHMcMurrayJJVApixaban versus warfarin in patients with atrial fibrillationN Engl J Med20113651198199221870978
   PubMed Web of Science ®Google Scholar
• GiuglianoRPRuffCTBraunwaldEEdoxaban versus warfarin in patients with atrial fibrillationN Engl J Med2013369222093210424251359
   PubMed Web of Science ®Google Scholar
• SchulmanSKearonCKakkarAKDabigatran versus warfarin in the treatment of acute venous thromboembolismN Engl J Med2009361242342235219966341
   PubMed Web of Science ®Google Scholar
• BauersachsRBerkowitzSDBrennerBThe EINSTEIN InvestigatorsOral rivaroxaban for symptomatic venous thromboembolismN Engl J Med2010363262499251021128814
   PubMed Web of Science ®Google Scholar
• BullerHRPrinsMHLensingAWAThe EINSTEIN-PE InvestigatorsOral rivaroxaban for the treatment of symptomatic pulmonary embolismN Engl J Med2012366141287129722449293
   PubMed Web of Science ®Google Scholar
• PrinsMHBauersachsRBellenBThe EINSTEIN InvestigatorsOral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studiesThromb J20131112124053656
   PubMedGoogle Scholar
• AgnelliGBullerHRCohenAThe AMPLIFY InvestigatorsOral apixaban for the treatment of acute venous thromboembolismN Engl J Med2013369979980823808982
   PubMed Web of Science ®Google Scholar
• HokusaiVTEIBullerHRDecoususHEdoxaban versus warfarin for the treatment of symptomatic venous thromboembolismN Engl J Med2013369151406141523991658
   PubMed Web of Science ®Google Scholar
• HuismanMVRothmanKJPaquetteMThe changing landscape for stroke prevention in AF: findings from the GLORIA-AF registry phase 2J Am Coll Cardiol201769777778528209218
   PubMed Web of Science ®Google Scholar
• SouthworthMRReichmanMEUngerEFDabigatran and postmarketing reports of bleedingN Engl J Med2013368141272127423484796
   PubMed Web of Science ®Google Scholar
• McConeghyKWBressAQatoDMWingCNutescuEAEvaluation of dabigatran bleeding adverse reaction reports in the FDA adverse event reporting system during the first year of approvalPharmacotherapy201434656156924644100
   PubMed Web of Science ®Google Scholar
• MajeedAHwangHGConnollySJManagement and outcomes of major bleeding during treatment with dabigatran or warfarinCirculation2013128212325233224081972
   PubMed Web of Science ®Google Scholar
• GoodmanSGWojdylaDMPicciniJPFactors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation)J Am Coll Cardiol201463989190024315894
   PubMedGoogle Scholar
• EerenbergESMiddeldorpSLeviMLensingAWBullerHRClinical impact and course of major bleeding with rivaroxaban and vitamin K antagonistsJ Thromb Haemost20151391590159626179293
   PubMed Web of Science ®Google Scholar
• HylekEMHeldCAlexanderJHMajor bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE trial (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation): predictors, characteristics, and clinical outcomesJ Am Coll Cardiol201463202141214724657685
   PubMed Web of Science ®Google Scholar
• BlekerSMCohenATBullerHRClinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trialThromb Haemost201611661159116427583312
   PubMed Web of Science ®Google Scholar
• BrekelmansMPBlekerSMBauersachsRClinical impact and course of major bleeding with edoxaban versus vitamin K antagonistsThromb Haemost2016116115516127010092
   PubMed Web of Science ®Google Scholar
• RuffCTGiuglianoRPBraunwaldEComparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trialsLancet2014383992195596224315724
   PubMed Web of Science ®Google Scholar
• AbrahamNSSinghSAlexanderGCComparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort studyBMJ2015350h185725910928
   PubMed Web of Science ®Google Scholar
• VillinesTCPeacockWFSafety of direct oral anticoagulants: insights from postmarketing studiesAm J Emerg Med20163411591327697441
   PubMedGoogle Scholar
• GrahamDJReichmanMEWerneckeMCardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillationCirculation2015131215716425359164
   PubMed Web of Science ®Google Scholar
• LarsenTBRasmussenLHSkjothFEfficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: a prospective nationwide cohort studyJ Am Coll Cardiol201361222264227323562920
   PubMed Web of Science ®Google Scholar
• HernandezIBaikSHPineraAZhangYRisk of bleeding with dabigatran in atrial fibrillationJAMA Intern Med20151751182425365537
   PubMed Web of Science ®Google Scholar
• LarsenTBSkjothFNielsenPBKjaeldgaardJNLipGYComparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort studyBMJ2016353i318927312796
   PubMed Web of Science ®Google Scholar
• HalvorsenSGhanimaWFride TveteIA nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulantsEur Heart J Cardiovasc Pharmacother201731283627680880
   PubMed Web of Science ®Google Scholar
• NoseworthyPAYaoXAbrahamNSSangaralinghamLRMcBaneRDShahNDDirect comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillationChest201615061302131227938741
   PubMed Web of Science ®Google Scholar
• LipGYKeshishianAKambleSReal-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysisThromb Haemost2016116597598627538358
   PubMed Web of Science ®Google Scholar
• DeitelzweigSBrunoATrocioJAn early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulantsCurr Med Res Opin201632357358226652179
   PubMed Web of Science ®Google Scholar
• BassandJPAccettaGCammAJTwo-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AFEur Heart J201637382882288927357359
   PubMed Web of Science ®Google Scholar
• LipGYHuismanMDienerHCRates of strokes and bleeding with dabigatran 150 and 110mg in clinical practice: The GLORIA-AF RegistryPaper presented at: American College of Cardiology2017Washington, DC
   Google Scholar
• Beyer-WestendorfJEbertzFForsterKEffectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC RegistryThromb Haemost201511361247125725739533
   PubMed Web of Science ®Google Scholar
• HeckerJMartenSKellerLEffectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC RegistryThromb Haemost2016115593994926791999
   PubMed Web of Science ®Google Scholar
• CammAJAmarencoPHaasSXANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillationEur Heart J201637141145115326330425
   PubMed Web of Science ®Google Scholar
• Pradaxa [package insert]Ridgefield, CTBoehringer Ingelheim Pharmaceuticals, Inc2011
   Google Scholar
• HariharanSMadabushiRClinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairmentJ Clin Pharmacol2012521 suppl119S125S21956605
   PubMedGoogle Scholar
• LehrTHaertterSLiesenfeldKHDabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulationJ Clin Pharmacol20125291373137821956604
   PubMed Web of Science ®Google Scholar
• Xarelto [package insert]Titusville, NJJanssen Pharmaceuticals, Inc2011
   Google Scholar
• Savaysa [package insert]Parsippany, NJDaiichi Sankyo, Inc2015
   Google Scholar
• DeedwaniaPCNew oral anticoagulants in elderly patients with atrial fibrillationAm J Med2013126428929623369212
   PubMed Web of Science ®Google Scholar
• BarcoSCheungYWEikelboomJWCoppensMNew oral anticoagulants in elderly patientsBest Pract Res Clin Haematol201326221522423953909
   PubMed Web of Science ®Google Scholar
• HylekEMEvans-MolinaCSheaCHenaultLEReganSMajor hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillationCirculation2007115212689269617515465
   PubMed Web of Science ®Google Scholar
• HalperinJLHankeyGJWojdylaDMEfficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)Circulation2014130213814624895454
   PubMed Web of Science ®Google Scholar
• SardarPChatterjeeSChaudhariSLipGYNew oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trialsJ Am Geriatr Soc201462585786424786913
   PubMed Web of Science ®Google Scholar
• SharmaMCorneliusVRPatelJPDaviesJGMolokhiaMEfficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysisCirculation2015132319420425995317
   PubMed Web of Science ®Google Scholar
• Eliquis [package insert]Princeton, NJBristol-Myers Squibb Company2012
   Google Scholar
• GageBFYanYMilliganPEClinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF)Am Heart J2006151371371916504638
   PubMed Web of Science ®Google Scholar
• PistersRLaneDANieuwlaatRde VosCBCrijnsHJLipGYA novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart SurveyChest201013851093110020299623
   PubMed Web of Science ®Google Scholar
• FangMCGoASChangYA new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) StudyJ Am Coll Cardiol201158439540121757117
   PubMed Web of Science ®Google Scholar
• ApostolakisSLaneDAGuoYBullerHLipGYPerformance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) studyJ Am Coll Cardiol201260986186722858389
   PubMed Web of Science ®Google Scholar
• Ruiz-GimenezNSuarezCGonzalezRPredictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE RegistryThromb Haemost20081001263118612534
   PubMed Web of Science ®Google Scholar
• RoskellNSSamuelMNoackHMonzBUMajor bleeding in patients with atrial fibrillation receiving vitamin K antagonists: a systematic review of randomized and observational studiesEuropace201315678779723407628
   PubMed Web of Science ®Google Scholar
• RogersKCSheltonMPFinksSWReversal agents for direct oral anticoagulantsCardiol Rev20162431031527548686
   PubMed Web of Science ®Google Scholar
• HarringtonARArmstrongEPNolanPEJrMaloneDCCost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillationStroke20134461676168123549134
   PubMed Web of Science ®Google Scholar
• YouJHNovel oral anticoagulants versus warfarin therapy at various levels of anticoagulation control in atrial fibrillation – a cost-effectiveness analysisJ Gen Intern Med201429343844624132628
   PubMed Web of Science ®Google Scholar
• ShahAShewaleAHayesCJMartinBCCost-effectiveness of oral anticoagulants for ischemic stroke prophylaxis among nonvalvular atrial fibrillation patientsStroke20164761555156127103018
   PubMed Web of Science ®Google Scholar
• HernandezISmithKJZhangYCost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney functionThromb Res201715012313027771008
   PubMed Web of Science ®Google Scholar
• CanestaroWJPatrickARAvornJCost effectiveness or oral anticoagulants for treatment of atrial fibrillationCirc Cardiovasc Qual Outcomes2013672473124221832
   PubMed Web of Science ®Google Scholar